American Society of Hirudotherapy

Chromosome-level genome assembly and anticoagulant protein annotation of the buffalo leech Hirudinaria bpling (Hirudinea: Hirudinidae)

Research article published in BMC Genomics (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentGenomics & ProteomicsKhan MS et al. · BMC Genomics, 2025

Abstract

This study aimed to obtain and analyze the chromosome-level genome assembly of Hirudinaria bpling, a species vital for aquatic ecosystem health and medical research. Understanding its genomic information is crucial for advancing its medical applications and elucidating its ecological role. We assembled the genome of H. bpling using a combination of PacBio HiFi long reads, Illumina sequencing, and Hi-C chromosome conformation capture techniques. This approach allowed us to achieve a high-resolution genome assembly with detailed chromosomal organization. The final genome assembly of H. bpling is 144.08 Mb, with an N50 size of 11.27 Mb, anchored onto thirteen pseudo-chromosomes. BUSCO analysis indicated a genome completeness of 96.20%. We annotated a total of 20,126 protein-coding genes and identified 18.80% repetitive elements within the genome. Phylogenetic analysis included nine other leech species, positioning H. bpling as a sister taxon to Hirudo manillensis. A comparative analysis focused on the identification of putative anticoagulant proteins (e.g. Hirudin, Antistasin, Hirustasin, Therostasin, Bdellastasin, Guamerin/Piguamerin, Gelin, Bplins, Saratin, Eglin C, Bdellin B-3, LDTI, Hyaluronidase, Destabilase, Apyrase, Leech carboxypeptidase inhibitor, Gamma-glutamyl transpeptidase, Lefaxin, Progranulin), identifying conserved regions and evolutionary relationships among these proteins across different leech species. As a medically significant species, H. bpling offers promising opportunities for research into anticoagulant therapies. This study provides a comprehensive genomic and phylogenetic analysis of H. bpling, offering new insights into leech genomics and the evolution of anticoagulant genes. The findings enhance our understanding of the genetic and evolutionary mechanisms underlying anticoagulant production in leeches.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsLeechesPhylogenyGenomeMolecular Sequence AnnotationAnticoagulantsChromosomesGenomics

Summary

Chromosome-level genome assembly and anticoagulant protein annotation of the buffalo leech Hirudinaria bpling (Hirudinea: Hirudinidae).

Why This Matters for Hirudotherapy

This study produced a chromosome-level genome assembly (144.08 Mb, 13 pseudo-chromosomes, 96.20% BUSCO completeness, 20,126 protein-coding genes) of the buffalo leech Hirudinaria bpling and used comparative analysis to map a large catalogue of putative anticoagulant proteins across leech species, including hirudin, antistasin, hirustasin, therostasin, bdellastasin, saratin, eglin C, destabilase, hyaluronidase and others. For hirudotherapy this is foundational genomic groundwork: the medicinal-leech secretome is the wellspring of the entire leech-derived drug-discovery story, and a reference genome plus annotated, conserved anticoagulant gene families gives researchers the molecular map needed to identify, compare and potentially produce these bioactive molecules. The honest caveat is that this is a genomic and phylogenetic resource study, not a clinical investigation; it characterizes the genetic potential for anticoagulant production and the evolution of these genes, but demonstrates no therapeutic effect, dosing, or patient outcome, and the species studied is Hirudinaria, not the European Hirudo medicinalis/verbana used in Western practice.

Citation

Chromosome-level genome assembly and anticoagulant protein annotation of the buffalo leech Hirudinaria bpling (Hirudinea: Hirudinidae)

Khan MS et al. · BMC Genomics, 2025

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.